Innovative financing into hepatitis B and C prevention and treatment in low and middle income countries

Statement 4 Feb 2025

156th WHO Executive Board (EB156): Individual statement on non-communicable diseases

On 4 February at the EB156 in Geneva, IFPMA delivered a statement on non-communicable diseases (NCDs).

Pharmacy-mediated substitution for biosimilars

Pharmacy-mediated substitution is a framework permitting substitution of medicines at the retail pharmacy without the consent of the prescribing physician. In this paper, IFPMA outlines a set of principles that can guide pharmacy-mediated substitution. While the principles are intended for the awareness of pharmacists, they can also relate to other healthcare providers, regulators, payers, and those involved in formulary and procurement decision-making.

Global regulatory approaches to post-approval changes in biotherapeutic products

IFPMA worked with Clarivate to study how different countries regulate post-approval changes (PACs) in biotherapeutic products. The research compared PACs guidelines across 21 countries and regions in Latin America (LATAM), Asia-Pacific (APAC), and the Middle East and Africa (MEA) to the World Health Organization (WHO) Guidelines on changes on biotherapeutic products. The findings reveal significant diversity in the level of convergence among countries and with the WHO Reference Guidelines, with a few notable trends.